Larimar Therapeutics Inc (LRMR)
7.76
+0.50
(+6.89%)
USD |
NASDAQ |
Mar 28, 11:07
Larimar Therapeutics Cash from Investing (TTM): 33.35M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 33.35M |
September 30, 2023 | -16.25M |
June 30, 2023 | 26.79M |
March 31, 2023 | 1.29M |
December 31, 2022 | -90.96M |
September 30, 2022 | -32.24M |
June 30, 2022 | -35.64M |
Date | Value |
---|---|
March 31, 2022 | 18.92M |
December 31, 2021 | 24.17M |
September 30, 2021 | -5.866M |
June 30, 2021 | 0.917M |
March 31, 2021 | 23.12M |
December 31, 2020 | 17.09M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-90.96M
Minimum
Dec 2022
33.35M
Maximum
Dec 2023
-2.716M
Average
1.29M
Median
Mar 2023
Cash from Investing (TTM) Benchmarks
Cogent Biosciences Inc | -97.82M |
ACADIA Pharmaceuticals Inc | 32.00M |
PTC Therapeutics Inc | -176.74M |
Renovaro Inc | -1.121M |
G1 Therapeutics Inc | 2.81M |